Biogen Idec to share latest neurology data at AAN 2014

Biogen Idec has announced that it will be presenting new data on its current and future neurological disease therapies at the American Academy of Neurology (AAN) annual meeting.

The company will attend the conference from April 26th to May 3rd 2014 in order to present more than 60 platform and poster presentations on data supporting its various therapy options.

Presentations will include two-year data from the pivotal phase III ADVANCE study for the investigational multiple sclerosis therapy Plegridy, as well as Tecfidera findings showing its efficacy among the more than 65,000 patients treated worldwide.

Further information will be shared on products such as Tysabri, Avonex, Fampyra, Anti-LINGO-1 and daclizumab high-yield process.

Dr Alfred Sandrock, group senior vice-president and chief medical officer at Biogen Idec, said: "The breadth of data we are presenting at AAN reinforces our enduring commitment to reducing the impact of multiple sclerosis and other serious neurodegenerative diseases."

Earlier this month, the company announced the appointment of Dr Adam Koppel as its new senior vice-president and chief strategy officer, effective as of May 15th 2014.